iBio reports Q1 EPS (11c), consensus (7c)

Reports Q1 revenue $100,000, consensus $25,000. “Unveiling our promising non-human primate data for IBIO (IBIO)-610, our long acting Activin E Antibody, marked a pivotal milestone for iBio,” said Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio. “The results demonstrate an extended half-life and the potential for highly convenient, low-frequency dosing, which could translate into improved patient compliance, while further validating our differentiated approach to fat-selective weight loss and long-term weight maintenance. Importantly, these findings reinforce IBIO-610’s promise as a next-generation therapy for cardiometabolic and obesity diseases. As we enter 2026, we look forward to advancing IBIO-610 and our broader pipeline to bring durable, transformative therapies to patients in need.”